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Abstract 
 
Background: A national roll-out of antiretroviral therapy in the public sector was started in 
2004, and Paarl was one of the first sites to start these services in the Western Cape. 
Operational research is required to guide the continuous improvement of such services. This 
research aimed to describe the characteristics of the treatment cohort started at TC Newman 
CDC’s ARV clinic in Paarl, to determine the retention in treatment rate and to assess the 
clinical and virological outcomes.  
Methods: A retrospective descriptive and observational study was done at the TC Newman 
ARV clinic in Paarl. All adult HIV positive patients that were started on antiretroviral therapy 
in the given time period were included. Patient and treatment data had been collected in an 
electronic database (e-register) and were extracted and analysed. 
Results: Starters: Out of the 2469 patients that were enrolled for ARV treatment between 
February 2004 and December 2010, 2254 started locally (the rest transferred in). 64% of 
them were female (decreasing rate over the years). Strugglers: By June 2011 51.5% of 
patients were still on ARVs, 6.9% patients had died, 16.7% had been ‘transferred out’and 
24.7% were reported as ‘Lost to Follow-up’. 40% of the attrition of the cohort occurred in the 
first 6 months, 70% in the first 18 months. Stayers: Of the 1172 patients retained after start 
at TC Newman CDC, 1023 (87.3%) were still on Regime 1 and 149 (12.7%) on Regime 2. 
Conclusions: The results of this treatment cohort (mortality, treatment retention and 
regimen durability) equal those in other published treatment cohorts, although very limited 
comparable data are available. However, the high ‘lost to follow-up’ rate is of concern and 
needs further investigation. Changes in the programme structure and environment tend to 
have an immediate effect on initiation numbers of new patients. 
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1 Introduction 
HIV infected individuals suffer from the chronic complications of immunodeficiency. The 
clinical symptomatology presentation of HIV/AIDS touches almost all possible medical 
disciplines and HIV/AIDS can ideally be ‘practised’ by all medical practitioners. This has not 
happened because of the growing complexity of the subject, intensive research underlining 
new treatment strategy, and the dynamics of the disease unmatched by other clinical 
conditions.  The system for providing clinical HIV management and the use of highly active 
antiretroviral therapy (ART) forms the foundation of what is referred to as “HIV medicine.” 
ART is a life-long intervention and determining the long-term outcomes and impact of 
treatment programmes is necessary to monitor and improve programme performance.  
In 2003 around 400 000 people were estimated to be receiving antiretroviral therapy in low-
income and middle-income countries.(1) At the end of 2008, more than 4 million people were 
receiving ART, representing a 10-fold increase in 5 years and a 35% increase in 1 year. (2) 
In view of the enormous scale and need for ART a simplified programmatic approach has 
been adopted to facilitate delivery of treatment.(3) 
With this dramatic expansion in HIV medicine, concerns have been raised that expanding 
access to ART in resource-poor settings will lead to ‘antiretroviral anarchy’ characterised by 
poor adherence to therapy, widespread viral resistance to medications and ultimately poor 
clinical outcomes. (4) 
 A number of programmes in resources-poor settings have demonstrated the feasibility of 
providing ART services (5,6) and have shown that in these instances outcomes in these 
programmes parallel outcomes in Europe and North America. (7,8)These services were 
provided by dedicated staff working in the field of “HIV medicine” and were linked to 
specialists and sub-specialists.(9)The good programmatic outcomes achieved by small, 
focused ART services, may be difficult to maintain as programmes grow in size and get 
integrate into general care.  (10,11) 
A systematic review of 33 patient cohorts, totalling 74 289 patients, from 13 African countries 
reported that only between 46 and 85% of patients remained in care at two years.(12) Rosen 
concluded that retention varies widely across programs and programs that have achieved 
higher retention rates can serve as models for future improvements. (12) 
Determinates of outcomes and the effect of differences in the health delivery system on 
outcomes, have not been studied in detail in resource limited settings. Understanding these 
issues is important to guide the development of effective ART programmes. 
In 2004 antiretroviral therapy was implemented at selected state health sector sites in the 
Western Cape. Since the implementation of ART, services for HIV-infected people have 
undergone a rapid change. Medical specialists and sub-specialists initially offered ART in 
tertiary institutions. Within 6 years, the ARV program expanded successfully to primary care 
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facilities and the services are largely driven by non-specialised doctors. With the increasing 
need and demand for ART it has become appropriate to expand services to include nurse 
clinicians. (8)The model of providing ART has changed in response to the changing needs of 
the local community, the health system and the availability of resources.  
This research aimed to document the development of the ART service and to review the 
changing patterns in outcomes and patient survival among patients attending a public sector 
community-based ART service. The TC Newman CDC’s ARV clinic was one of the first 
clinics to be accredited in the Western Cape that was not directly linked to an academic 
hospital. A standardized monitoring system to track the number of patients starting ART and 
to determine four key outcomes (those who are alive and on ART, those who are dead, 
those who have transferred out to another facility and those who have been lost to follow-up) 
was set up. The data collected was used to describe the characteristics of the treatment 
patient cohort groups started at the facility. 
 
2 Methods 
2.1 Setting 
The Cape Winelands District is centrally located in the Western Cape Province, the largest 
sub-district in the Cape Winelands is Drakenstein. The area is known for towns such as 
Paarl, Wellington, Gouda and Saron and it comprises an area of 1 538 km². The agriculture 
industry plays a significant role in the region’s economy and Paarl serves as an agricultural 
service centre for the surrounding intensive farming areas.  
The Drakenstein Local Municipality has a population of 194 231 (2006) which is expected to 
decline by –0.2 % per annum to reach 192 336 by 2010. The population is predominantly 
coloured (64 %) and black (22%) with a small white population (14%). Half of the population 
is under the age of 30, with males and females evenly split.     
Total unemployment stood at 22.8 % in 2001, comparing poorly with the district average of 
18.4%. When seasonal unemployment is considered unemployment increases to 24.1% 
The Drakenstein sub-district record high levels of TB prevalence (1 196 TB cases per 100 
000) and low TB cure rate (69 % in 2005) (13) 
The proportion of the population infected by HIV/AIDS remains high and stable at 5.4% from 
2005 –2010. (The population figures are based on the ASSA Demographic and AIDS Model 
2003) 
In 2008 19 433 people (10 % of population) were tested for HIV at state clinics in 
Drakenstein, 2 136 people tested positive for HIV. 4 099 pregnant woman were tested for 
HIV with 462 testing positive (11%) In 2008 it was reported that only 24 patients of the 2 136 
people tested positive for HIV were under 15 years. tested positive for HIV. (14) 
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2.2 Medical facilities and health care: 
Most HIV+ residents rely on health services delivered by the state. There are 18 primary 
care HIV clinics within the sub-district; each clinic has staff able to provide voluntary testing 
and counselling, together with prophylaxis and outpatient management of common HIV 
opportunistic infections. TC Newman (Paarl) and Wellington community day centres (CDC) 
give support to the primary health care clinics.  Patients requiring inpatient care are referred 
to a local 250-bed secondary care hospital or a local 80-bed TB hospital.  
 
2.3 Development of ART services 
Paarl was one of the national pilot sites for implementing the Nevirapine based PMTCT 
programme in 2001.  
A dedicated HIV/AIDS service for HIV infected adults and children were established in 
January 2003 at TC Newman CDC. A full package of prophylaxis, treatment of opportunistic 
infections and palliative care was provided.  
The National Minister of Health launched The Operational Plan for the Comprehensive Care, 
Management and Treatment of HIV and AIDS in South Africa in November 2003 which for 
the first time allowed for the widespread provision of an antiretroviral service for patients who 
needed them in the public sector.(15,16) 
Up till then the only patients who were started in the Western Cape on antiretroviral 
treatment, in the public sector, were those managed by Non-governmental organizations 
(MSF and Hannan-Crusaid) and as part of clinical drug trials in tertiary academic hospitals. 
These programmes observed encouraging results in providing ARV treatment at primary 
health care level in the public sector and confirmed that ARV treatment is a feasible and a 
cost-effective intervention and can significantly reduce the morbidity and improve the 
survival rates of people living with HIV/AIDS.(6,9,17) 
Initially, the plan was to provide a service where the expertise and infrastructure was already 
in place to provide patients with immediate access to ART. There were a lot of patients 
waiting for ARV treatment at the dedicated HIV/AIDS clinic at TC Newman (Paarl), but the 
staff had no experience in providing antiretroviral treatment. With the support of Non-
governmental organisations and the back-up tertiary academic hospitals the first patients 
were started on ARV treatment in February 2004 in Paarl.      
In February 2004 the ARV treatment site in Paarl was the only service available for people 
living in the West Coast Winelands region. Patients travelled up to 300 kilometres to get 
ARV treatment. The need to provide equitable access to ARV treatment for all patients in the 
region stimulated/resulted in  the opening of satellite ARV sites and service points in the sub-
district. Mobile teams from TC Newman ARV clinic provided training, mentoring and clinical 
support to the new sites.  
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By February 2005 373 patients were receiving ARV treatment at 5 different sites in the 
district. Stable patients on ARV were transferred out from TC Newman to the sites in 
neighbouring towns. By February 2006 more than a 1 000 patients had been started on 
ARVs and by February 2007 2115 patients received ARV treatment in the region.   
By now most patients from outside Paarl were seen at clinics closer to them, but all patients 
from Paarl were seen at T C Newman hospital. The infrastructure needs of the ARV clinic at 
TC Newman became a big concern. As the clinic became more and more saturated, a 
bottleneck in patient enrolment was created and patient retention was undermined. In order 
to relief the TC Newman ARV site 4 satellites ARV sites were started at the 4 biggest 
“feeder” primary care clinics at the end of 2007. A cluster of ARV service sites was created 
in Paarl since 2008. In February 2011, 7 years of providing ARV treatment at T C Newman 
CDC and in Paarl was celebrated.  
 
2.4 Clinical Care, protocols and documentation: 
Enrolment and treatment of patients followed the National Ministry of Health ART guidelines. 
(16) 
Clinical services are provided by a team comprising of doctors, nurses, pharmacy staff and 
counsellors with good continuity of care. Reasonable referral networks exist with the local 
hospitals and other primary care services such as Tuberculosis services.  
Doctors are mainly responsible for treatment initiation, regimen changes and dealing with 
specific problems, while nurses provide most of the routine patient follow-up for those on 
ART, according to standardized protocols. 
Standardized flowchart algorithms for the management of adverse events and virological 
failure guide doctors and nurses in safely monitoring patients and advise when and how to 
change treatment. (15) 
 
The clinical protocol stipulates that patients begin treatment: 
WHO clinical stage 4 or have a CD4 lymphocyte count of < 200/μl 
In December 2009 the protocol was modified to also include pregnant women and patients 
co-infected with tuberculosis with CD4 lymphocyte counts of <350/μl or a clinical stage 3 or 4 
disease. Since August 2011 all patients with CD4 lymphocyte counts of <350/μl qualify for 
treatment.  
Additional criteria: Nominating a treatment assistant to assist with adherence 
Receiving a home-visit to verify the family environment 
Evidence of disclosure  
Attendance on time for at least 3 previous appointments. 
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The consultation frequency for those on ART is determined by the clinical protocol: 
fortnightly until 2 months on ART, monthly until the first year on ART, and the 2-3 monthly 
thereafter. Patients are seen more frequently if clinically indicated.  
A strong patient-centred approach is used to promote adherence. This includes a 
comprehensive counselling infrastructure providing for one-on-one individual counselling 
with trained lay-counsellors and regular support groups. 
 
2.5 Study design and methodology 
 
2.5.1 Research Question 
 
What are the outcomes in patient survival, patient retention and virological control of HIV+ 
patients enrolled in the ARV programme since February 2004 up to December 2010 at TC 
Newman CDC, Paarl, Western Cape? 
 
 
2.5.2 Aim 
 
The aim of this study was firstly to identify available data, to analyse the data and to evaluate 
the outcomes of a state health care (semi-urban, non-academic) ART programme in the 
Western Cape.  
Secondly, the aim was to contribute to the continuous improvement of the quality of care and 
the development of the programme design. 
 
2.5.3 Objectives 
The objectives were to 
 collect information on the rate of enrolment and characteristics of patients enrolled on 
ART (“the Starters”) 
 determine the proportion of patients retained on ART (“the Strugglers”) 
 assess the clinical and virological outcomes of the patients started on ART (using six 
annual cohorts) – (“the Stayers”) 
 give recommendations for monitoring outcomes in future. 
 develop suggestions for the improvement of the model of care. 
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2.5.4 Study design 
This is a retrospective descriptive study. Clinical records of patients were reviewed and 
information together with laboratory results was transferred to a data basis. 
 
 
2.5.5 Research population and sample 
All adult HIV positive patients enrolled on antiretroviral treatment at the T C Newman CDC in 
Paarl Patients who were 18 year or older when they started their treatment were included. 
Women who received ARVs solely for the prevention-of-mother-to-child-transmission during 
pregnancy were excluded. The complete treatment cohort in the given time period was 
included and no sampling was performed. 
 
 
2.5.6 Data Source and analysis 
When the data capturing for the project was started in 2010, a paper based system was in 
place by which clinical information, out of patient records, was transferred to a paper 
register. Data needed for the study was captured from the paper register and transferred into 
an excel database 
The growing number of patients created a complex amount of data, and the delay between 
the occurrence of an outcome event and its documentation on the paper based register 
undermines the quality of data required for the study. A “live” electronic data capturing 
system was introduced during 2010. Data from the paper register was “back-captured” onto 
the electronic register, and after completing the back-capturing of the data, the paper 
register was discontinued. 
With the new electronic data capturing system, information was directly (‘live’) transferred 
from the patient file to the electronic register. It was possible to transfer data captured in the 
electronic register to Excel Datasheets. At the end of June 2011, the data in the electronic 
register of all the patients enrolled at TC Newman ARV clinic since February 2004 up to 
December 2010, were transferred to an Excel Datasheet. A digital file of the data sheet, 
without the patient names, is available.  
The results of the study are based on analysing the data transferred out of the electronic 
register. To help with the interpretation and visualisation of data, Tableau software® was 
used. 
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2.5.7 Describing the results 
ARV services at TC Newman CDC have undergone a rapid change since their inception in 
2004. Quality improvements were implemented at regular intervals, resulting in a need to 
document the impact of the changes made on patient outcomes.  
As one example, a new way of categorising the differing needs of patient attending the ARV 
clinic was introduced to the clinic in 2009 by Dr David Pienaar, then director in the Western 
Province HAST management team. The demand on patients to attend health facilities for 
drug pick-ups and clinical assessments needed to be reduced by either reducing follow-up 
visits to once every 2 or 3 months or by providing decentralized ART services. To help staff 
identifying patients ready for decentralizing and reduced visits to the clinic the following 
terms were created: 
 Starters: refers to new patients at the clinic and during their first year on ARV 
treatment, 
 Strugglers: refers to all those patients in “danger” of getting lost to the programme 
and those lost to the programme  
 Stayers: refers to all the patients that are “stable” on ARV treatment. 
In accordance with this concept, the results of this study will be presented in three sets of 
data, each focusing on a “different group of patients” and the processes in the services 
supporting the groups of patients. 
 
2.5.8 Ethical considerations 
The research proposal was approved by the Health Research Ethics Committee (HREC) of 
the Faculty of Health Science, University of Stellenbosch. 
Operational research focusing on patient retention and virological outcomes has been done 
before in different settings, but limited information is available on outcomes in resource 
limited setting. Understanding determinants of virological outcomes and patient retention in 
different operational setting is important to guide the development of effective ART 
programmes.  Through improvements based on the outcomes of this research, the study can 
benefit the individuals on treatment and future patients entering the treatment programme. 
This is a retrospective study and thus no clinical risks for participants are foreseen. 
All information was collected and handled in a strictly confidential way. Members of the clinic 
staff collected the data, and after collecting the data the information was anonymous. .No 
names or other individual identifiers were used in the discussion of results. 
Given the retrospective nature of this research, obtaining informed consent from the subjects 
was not feasible and a waiver of consent had been obtained from the ethics committee. 
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3 Results 
3.1 Objective 1: Patient enrolment into the ARV programme (The starters) 
The aim of this set of results is to describe, develop an understanding of and evaluate the 
factors affecting the enrolment of the patients into the ARV programme.  This analysis 
included 2469 adult patients who were enrolled for ART at TC Newman CDC from 1 
February 2004 until 31 December 2010.  The study population included all adult patients that 
were ever enrolled at TC Newman, no one was excluded. 
 
3.1.1 Enrollment of patients 
Patients who were enrolled into the programme were either ‘New’ (a patient starting ARV 
treatment for the first time) or ‘Transferred In’ (a patient already on ARV treatment who 
moved in from another clinic).  The term ‘enrolled’ will be used when referring to patients 
both ‘New’ and ‘Transferred In’.  The term ‘starter’ will be used when referring to ‘New’ 
patients only. 
 
Table 1: Number of patients enrolled annually for ART at TC Newman ARV clinic 
 2004 2005 2006 2007 2008 2009 2010 Total 
New 189 263 422 427 251 334 368 2254 
Transferred in 20 20 30 41 39 32 33 215 
Total 209 283 452 468 290 366 401 2469 
 
Table 1 shows that only 215 of the 2 469 patients ever enrolled at TC Newman CDC were 
‘Transferred In’.  The majority (91%) of the patients were started newly on ART at TC 
Newman CDC. The ratio between ‘New’ and ‘Transferred In’ patients remained fairly 
constant over the 6 years. 
 
Table 2: Number of ‘New’ patients enrolled annually for ART at TC Newman by gender 
 2004 2005 2006 2007 2008 2009 2010 Total 
Women 127 
(67%) 
184  
(70%) 
271 
(64%) 
283  
(66%) 
165  
(66%) 
201  
(60%) 
209 
(56%) 
1440 
(64%) 
Men 62 79 151 144 86 133 159 814 
Total 189 263 422 427 251 334 368 2254 
 
On average two thirds (64%) of the patients started on ARVs were women. 
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Figure 1: Number of patients started on ART annually at TC Newman ARV clinic from January 
2004 to December 2010 divided into female and male patients 
 
An interesting trend seems to be developing over the seven years, where the first five years 
were marked by an average of 66.6% of the patients started being women and in the last 
two years this percentage has dropped to under 60%. This trend would justify further 
investigation. 
 
Table 3: Number of patients enrolled for ART TC Newman by age intervals 
 ART Start Date 
Age 
(years) 2004 2005 2006 2007 2008 2009 2010 
Grand 
Total 
15-19 1     2 2 5 
20-24 2 3 6 3 7 20 27 68 
25–29 20 15 37 45 49 67 71 304 
30-34 82 156 91 90 53 78 88 638 
35-39 35 34 112 130 78 80 80 549 
40-44 33 33 86 75 44 47 46 364 
45-49 13 22 54 50 29 36 41 245 
50-54 12 11 41 37 11 16 24 152 
55-59 4 3 12 25 11 9 15 79 
60-64 4 3 9 6 5 7 4 38 
65-69 3 2  4 3 3 2 17 
70-74   4 3  1 1 9 
75-79  1      1 
Grand 
Total 
209 283 452 468 290 366 401 2469 
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When looking at the age demographics, it shows that 48% of patients are between the ages 
of 30-40 years old.  Furthermore, 85% of the patients are between 25 and 50 years old.  
 
Table 4: Number of patients enrolled for ART at TC Newman by gender and age 
 Gender 
Age  Female Male Grand Total 
15-19 4 1 5 
20-24 48 20 68 
25–29 229 75 304 
30-34 450 188 638 
35-39 354 195 549 
40-44 224 140 364 
45-49 112 133 245 
50-54 70 82 152 
55-59 36 43 79 
60-64 15 23 38 
65-69 6 11 17 
70-74 5 4 9 
75-79 1  1 
Grand Total 1554 915 2469 
 
Men on treatment are older than the women on treatment (Table 4).   
 
 
3.1.2 Rate of patient recruitment 
The rate at which patients are enrolled can be related to a lot of known and unknown factors. 
Some of these issues can be site and time specific or can be generalised issues such as 
access to the clinic, number of patients in need of ART treatment, the protocol, number of 
staff, and turnover of professional staff, infrastructure needs, the opening of new ART 
services points and the use of temporary employed staff 
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Figure 2: Number of patients started on ART per month at TC Newman ARV clinic, with annual 
averages 
 
Figure 2 summarises the average number of patients started at TC Newman CDC on an 
annual basis. 
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3.2 Objective 2:   Programme retention and outcomes (The strugglers) 
 
The aim of this set of results is to describe, develop an understanding, and evaluate the 
outcomes of patients after they were initiated on ARV treatment.  Only one outcome per 
patient was documented. Outcomes were divided according to the four following definitions:  
 On ART: The patient received ARV treatment and care at the clinic during the past 3 
months. 
 Died: The patient died after starting on ARV treatment. 
 Lost to Follow-up: No documentation for the patient receiving ARV treatment and 
care in the last 3 months. If the patient returns and starts with treatment or 
information about the patient's outcome is received (e.g. death or transfer-out are 
reported) the lost to follow-up patient’s outcome status would be changed. 
 Transferred/Moved Out: The patient was transferred to another ARV clinic or moved 
to another town. 
 
Table 5: Outcomes as reported by the end of June 2011 of patients enrolled in the ARV 
programme at TC Newman 
 Outcome Number of patients % of total patients 
enrolled 
On ART 1272 51.5 % 
Died 171 6.9% 
Lost to Follow-up 612 24.8% 
Transferred/Moved Out 414 16.8% 
 2469 100% 
 
 
By June 2011 (Table 5), 171 (6.9%) patients had died after enrolment into the ART 
programme at TC Newman CDC, 51.5% of patients were still on ART, 16.7% 
Transferred/Moved Out and 24,7% of patients were reported as Lost to Follow-up. Retention 
in care (On ART + transferred (moved out)/total number of patient enrolled) was 68.2%    
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Figure 1 Time on treatment as a variable against outcomes of patients enrolled into ART 
 
Table 6: Time on treatment as a variable against outcome. 
Outcome 2004 2005 2006 2007 2008 2009 2010 Total 
On ART 100 
47,8 % 
135 
48.2% 
230 
51% 
240 
51.2% 
140 
48.2% 
191 
52% 
236 
58% 
1272 
Died 
 
36 
17.2% 
29 
10.2% 
36 
8% 
25 
5.3% 
18 
6.2% 
11 
3% 
16 
3.9% 
171 
Lost to Follow-up 
 
40 
19.1% 
68 
24% 
127 
28% 
110 
23.5% 
82 
28% 
98 
26.7% 
87 
21.6% 
612 
Transferred/Moved 
out 
33 
15.7% 
51 
18% 
59 
13% 
93 
19.8% 
50 
17.2% 
66 
18% 
62 
15.4% 
414 
Retention in care 
(On ART + 
Transferred/moved 
out) 
 
63.5% 
 
66.2% 
 
64% 
 
71% 
 
65,4% 
 
70% 
 
73.4% 
 
 
Analysing time on treatment as a variable against outcomes (refer to Figure 3 and Table 6), 
it was found that 17,2 % of the patients enrolled into treatment in 2004 had died, while only 
3% of the patients started in 2009 died.  Only 19.1% of the patients started in 2004 were lost 
to follow-up, while 28% of patients started in 2008 were lost to follow-up. There was no 
significant difference between the numbers of patients transferred out per year. The data 
show no clear change in outcome trends with variation of time on treatment. 
 
 
% of patients started  
on ART 
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Table 7: Gender as a variable against outcomes of patients enrolled at TC Newman 
Outcome Female % of 
Females 
Male % of Males Total % of total 
On-Art 834 
 
53.6% 438 
 
47.8% 1272 51.5% 
Died 82 
 
5.2% 89 
 
9.7% 171 6.9% 
Lost to Follow-up 388 
 
24.9% 224 
 
24.4% 612 24.7% 
Transferred/Moved out 250 
 
16% 164 
 
17.9% 414 16.7% 
Total 1554 
 
 915 
 
 2469  
 
Analysing gender as a variable against outcomes was found that 9.7% of males had died 
and 5.2 % of females died. (Table 7) 
 
 
Figure 2 Total number of patients not on treatment at the end of June 2011 as a function of 
time in months after initiation of ART.  (Null = patients still on ART) 
 
Figure 4 illustrates that of all the patients not on treatment anymore, 43% left (either Died, 
Lost to Follow-up or Transferred/Moved Out) the programme between 0 to 6 months after 
treatment initiation and 70 % left between 0-18 months after treatment was started. 
Time in months 
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Figure 3 Summary of time since ART initiation of patients who died 
Figure 5 shows that 49.4% of all patients who died did so in the first 6 months after treatment 
initiation and another 17,2% died between 6 and 12 months on treatment. 
 
 
 
Figure 4 Summary of time since ART initiation of patient who were Lost to Follow-up 
 
The primary reason for patients not staying in the programme was Lost to Follow-up (refer to 
Figure 6), 44.9% of patients became lost to follow-up within 0-6 months, 14,8% between 6-
12 months and another 13.3 % between 12-18 months 
 
 
Figure 5 Summary of time since ART initiation of patients who Transferred/Moved Out 
 
.The patient who Transferred/Moved Out showed a similar pattern (Figure 7). 
Time in months 
Time in months 
Time in months 
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3.3 Objective 3: Regimen 1 durability and “On-treatment virological suppression” 
(The stayers) 
 
The aim of this section is to describe, understand and evaluate programme performance of 
the patients that are on ARV treatment at the clinic.  Of the 2254 patients that started on 
ARV’s, 1172 (51.9%) patients were still on treatment at the end of June 2011. Regime 1 
Durability and “On-treatment virological suppression” are determinates to evaluate the 
performance of the clinic in providing care to patients on treatment. 
To analyse this group only patients that were started on ARV treatment at TC Newman were 
included. Patients remaining on treatment were grouped together, based on the ARVs they 
were receiving. Patients were classified as: on Regime 1 or as a patient on Regime 2.  
Regime 1 is (NNRTI based) and is used as starting regime.  Regime 2 is a “PI based” 
second line regime and is used for patients who have failed Regime 1. 
At the end of June 2011, of the 1172 of the patients started at TC Newman CDC   1023 
(87,3%) were still on Regime 1  and (149)12.7% on Regime 2  
 
 
Figure 6 Time on treatment and number of patients on Regime 1 and Regime 2 
 
Table 8: Patients still on Regime 1 as percentage of all patients still on treatment after 
specified time  
Time in 
months 
73-84 61-72 49-61 37-48 25-36 12-24 6-12 
% of 
patients  
83, 3% 81,7% 77,6% 86,3% 91,3% 90% 98% 
 
 
Figure 8 and Table 8 illustrate time on treatment as a variable against number of patients on 
Regime 1. Even with the increase in time the % of patients on treatment on Regime 1 stayed 
high compared to the number on Regime 2.  
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Table 9: Outcomes of viral load testing of the patients on treatment 
Number of patients 
on treatment 
Viral load not done  Lower than 
Detectable level VL 
 Detectable 
1172 215 911 153 
 18.3% 85.5% 14.3% 
 
On-treatment virological suppression rates are important determinates of programmatic 
outcomes.  Patients on treatment were grouped together, according to the last recorded viral 
load measurements. The groups were classified as: No Viral load recorded, Viral loads < 
400 copies/ ml = LDL, Viral loads > 400 copies/ml = Detectable    
Viral loads were not reported on 18.3% (Table 9) of the patients remaining in treatment. 
85.5% of the viral loads done were ‘Lower than Detectable Levels’.  Of the patients with 
Detectable Viral loads, 6.6% were on Regime 1 and 6.5 % on Regime 2.   
 
 
Figure 7 Summary of time on treatment of patients on Regime 1 and Regime 2 and Viral load 
control 
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Figure 8 Percentage of patients on Regime 1 and Regime 2 and Viralogical outcomes.  
 
Figure 9 and 10 demonstrate good durability of Regime 1 over time.   
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4 Discussion: 
Over time the quality of data capturing and analysing data became an increasing concern for 
the staff and management of the clinic. In the absence of curative treatment, lifelong follow-
up of patients on ART is required to monitor adherence, treatment response and adverse 
effects. A growing amount of increasingly complex information needs to be reviewed at each 
visit, and new data must be added to the record. 
 
Cornell studied data collection and data quality at 11 ART programs in South Africa and 
concluded that although South Africa has implemented the largest treatment programs in the 
world, the ability to monitor the programs closely has not kept pace with expansion. (18) 
 
Foster suggested that promoting appropriate and sustainable databases and systems to 
trace patients should be a priority in the context of scaling up ART. (19) Electronic databases 
can play an important role, particularly as numbers of patients in ART sites increase, but for 
this to work adequate human resources and staff training are essential.  
 
In line with above recommendations and  to facilitate the collection of good-quality data and  
the transition from a paper based register to an electronic data based register a full time data 
capture was employed during the period of data collection for the study. The extra staff 
member helped in reducing the pressures facing the clinic and ensured a complete set of 
data.  
 
4.1 Objective 1: Enrolment of patients “The Starters” 
 
Access to antiretroviral therapy expanded rapidly in the sub-district and compare well with 
the 10 fold expansion in 5 years of ART in low- and middle-income countries reported in 
2009. (2)  
 
4.1.1 Proportion of transferring in 
 
The ARV service at T. C. Newman CDC was one of the first ARV sites in the more rural 
areas of the Western Cape. It was expected that a lot of patients on treatment will be 
transferred to the “new” site. It was also argued that transferred in patients are a “difficult 
group” to integrate into the “culture” of the clinic, because they were not part of the standard 
patient education programme. In conclusion the proportion of “transferred in patients” at the 
TC Newman CDC is small compared to the number started at the clinic. It is unlikely that 
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the” transferred in patients” have a significant impact on the functioning and outcomes of the 
clinic. 
 
4.1.2 Gender distribution 
Data disaggregated by gender shows that about 60% of adults who were receiving ART in 
low- and middle income countries were women. (2) At TC Newman 62.9% of the patients 
started on ARV were women. In the first 5 year 66.6 % of the patients started at the clinic 
were women, the last two years the percentage has dropped to 58%. This trend justifies 
further investigation in order to identify and support strategies that enhance men’s 
acceptability of ART services. 
Studies had shown that men are less likely to access treatment, present with more advance 
stages of HIV disease and have a higher risk of defaulting. (20) (21) 
 
4.1.3 Age distribution 
It is the young adults in the population that are the worst affected by HIV with 48 % of the 
patients at the clinic between the ages of 30-40 years. Staff working in the ARV clinics needs 
to adjust to the needs of the younger adult, like reproductive health needs and the need for 
flexibility to accommodate the working adult. 
 
4.1.4 Enrolment trends 
The fluctuation over time in the number of patients enrolled is closely related to 
developments and scale-up events at clinic level. Changes in the programme structure and 
environment tend to have a direct effect on the numbers of patients initiated. 
 For example:  
. 
 Creating capacity for ART service delivery: 
In the first two years of the programme the enrolment of new patients at the clinic 
was limited to two days a week, because of the availability of staff and physical 
space. It is documented that the chronic shortage of health care workers is a major 
bottleneck to health provision and scaling up treatment. (17) (22) The average 
number of patients started in 2004 was 19 patients per month and in 2005, 22. In 
2006 the number of patients enrolled monthly increased to an average of 35 patients 
reaching a maximum of 60 patients in one month of the year. The increase in 
numbers in 2006 follow on the employment of full time doctors at TC Newman CDC 
ART clinic and the ability of the team to put patients on treatment for 5 days a week. 
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 Physical space was a critical constraint in the expansion of the programme.  
The sharp increase in total number of patients on treatment since 2006 put a lot of 
pressure on the need for more physical infrastructure. In 2007 the clinic was 
relocated and patients were seen at three different rooms in three different corners of 
the facility. The lack of physical space was one of the main reasons for the drop in 
the number of patients started on treatment in the second part of 2007. Infrastructure 
as a key barrier to implementation of ART was identified and it was agreed that new 
infrastructure were needed, but it would take 3 years for the infrastructure to catch up 
with the patient needs. Physical space as barrier to implementation of ART access 
was also identified by Bekker. (9) 
 
 Decentralization  of ART services: 
With the help of non-governmental organisation, ART services were decentralised to 
Primary Health Care clinics in the Drakenstein sub-district. The decentralisation of 
ARV services started at the end of 2007 and had an impact on the enrolment at TC 
Newman CDC as seen by the decline in the number of patients enrolled in 2008. In 
2008 only 21 patients were on average started on treatment per month, but 4 new 
ART service points were available in the Drakenstein sub district. Decentralization 
and task shifting has been shown to work in a number of settings (16) (23 ) (24)  
 
 Reduction of the frequency of visits for stable patients 
In 2009 a new strategy at the clinic focussed on identifying stable patients and 
reducing follow-up visits to the clinic to once every 2 or 3 months. Clinic staff had 
more time to initiate patients and since 2009 (average of 28) there was a steady 
growth to an average of 31 per month. 
 
 
4.2 Objective 2: Evaluating outcomes: The Strugglers 
 
Harries documented that good ART clinic practise must include reliable ascertainment of 
outcomes of death, loss to follow-up and the formal recording of transfer outs from one ART 
facility to another. (25) 
It was possible to identify treatment outcomes at the clinic through regular scrutiny of the 
paper-based files and register, but it was labour intensive,  done only quarterly and by the 
time the treatment outcome report became available, it already needed updating. Introducing 
the electronic registered made it possible to have a daily treatment outcome report after all 
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the patients visits were entered. The sustainability and timeliness of the electronic register 
greatly enhanced the ability of the clinic to trace patients who are either late for 
appointments or who have been recorded at lost to follow-up. 
 
4.2.1 Retention in care 
The scale-up of ART has been one of the success stories of sub-Saharan Africa, however 
tempering the success is a growing concern about patient retention 
 
We defined attrition from ART programs to include patients who died or were lost to follow-
up and retention were defined as the opposite of attrition (i.e. 1- attrition) Using the definition 
63.5 % of the patients started on ART in 2004 (73-84 month on treatment) are retained in 
care. The retention in care for the 6 cohort groups averaged 68.8% and with a variation of 
(63.5%- 73.5%) 
 
This compare well with analysed done by Fox on 33 sources describing 39 cohorts and 
226 307 patients on ART in sub-Saharan Africa. It was found that the overall retention by 24 
months averaging 70%-77% and overall retention by 36 months averaging 65%-72%.(26) 
 
Measuring retention in care is critical for determining the effectiveness of programmes and 
can be used as a proxy for the quality of care. (5 ) Tassie also reported that the countries 
with highest burden of patients, South Africa, Kenya, Nigeria, India, Zambia did not report on 
retention as indicator.  
 
By June 2011, 6 and a half years since the start of clinic, 6.9% patients had died after 
enrolment into the ART programme, 51.5% of patients were still on ART, 16.7% 
Transferred/Moved Out and 24,7% of patients were reported as Lost to Follow-up. These 
findings at the TC Newman clinic document that retaining patients in care for lifelong 
treatment is difficult. 
 
4.2.2 Mortality rate 
The overall low mortality rate of 6.9% in the programme was encouraging. Of all the patient 
who died after enrolment, 49.4% of patients died in the first 6 months after treatment 
initiation and another 17,2% died between 6 and 12 months on treatment. These findings 
compare well with other programmes, Bekker reported a 7% mortality rate in Guguletu with 
63% of deaths occurring in the first 90 days of ART.(9) and Lawn reported that 8% to 26% of 
patients entering ART programmes die in the first year in African settings. (27) 
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The low mortality rate at TC Newman needs to be interpreted with caution, because the high 
Lost to Follow-up rate can mask a higher mortality rate.  
 
Analysing gender as a variable against outcomes it was founded that 9.7% of males died 
and 5.2 % of females died. This finding is consistent with other studies documenting men 
having a higher mortality risk. (28) 
 
The reasons for patients dying on treatment at the clinic need further investigation and to 
reduce the death rate intervention need to focus on reducing early on treatment mortality. 
 
4.2.3 Lost to follow-up rate. 
 
Of the patients not staying in the program 54% were reported as Lost to follow up, 35% 
reported as transferred out and 11% died. We do not have a good understanding of reasons 
for patients not returning to care at the clinic. A systematic review and meta-analysis of 
studies that traced patients who were Lost to follow up in ART programmes in resource-
limited settings showed that the outcome of over a third of patients remained unknown. (29) 
and among those traced 20% to 60% had died. Common reasons included the transfer to 
another ART site, financial problems, improvement or deteriorating health and stigma. (29)  
 
Of the patients reported as Lost to follow-up 44.9% become lost to follow-up within 0-6 
months. The results confirm the results of previous studies that once a patient have initiated 
ART and survived the initial few months of treatment the risk of lost to follow up and death is 
low. (30)  
 
To understanding the Lost to Follow up group it is recommended that, reasons for lost, and 
outcomes after Lost to Follow-up, get documented at TC Newman CDC. For this patient 
tracing procedures need to be in place. (31)  
Harries, Zachariah, Lawn and Rosen presented and discuss key interventions they believe 
might help with improving patient retention.(25) Some of the strategies (the need for simple 
and standardized monitoring systems to track what is happening, reliable ascertainment of 
true outcomes of patients lost to follow-up, implementation of measures to reduce early 
mortality in patients both before and during ART, the use of simple, non-toxic ART regimes 
and the decentralization of ART care to health centres and the community) were 
implemented at the TC Newman CDC. Operational research at facility level is needed to 
evaluate the outcome of these quality improvement strategies. 
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4.2.4 Transferred/Moved out 
Because of the expansion and decentralization of ART services an increasing number of 
patients were transferred between treatment centres. Good communication and sharing of 
patient information between treatment centres are needed. Implementing the electronic 
register at more clinics will help to identify patients that have moved between clinics. 
.  
4.3 Objective 3: Evaluating patients on treatment: The Stayers 
 
4.3.1 Regimen durability 
Six years after the programme was started at TC Newman CDC, 87.3% of the patients on 
treatment were still on Regime 1 and 12.7% on Regime 2.Even with the increase in time the 
% of patients on treatment on Regime 1 stayed high compared to the number on Regime 2. 
Change from Regime 1 to Regime 2 was due to treatment failure. Boulle reported on similar 
settings to TC Newman that at 2 years, 3.7% of adults were on Regime 2, rising to 17.9% at 
4 years. (32) 
 
4.3.2 Virological outcome 
Routine viral loads were done to monitor efficacy of ART. Of the patients remaining in care, 
85.5% of the last viral load reported was ‘Lower than Detectable Levels. The proportion of 
patients with “Lower than detectable Levels” compares favourably with those reported in 
other studies. (6) (33) (34) 
The stable patients on treatment form the bulk of the patients visiting the clinic daily. They 
are an ever growing group and because of the nature of ARV treatment will never been 
discharge out of the ARV services. There are a need to develop sustainable processes and 
platforms at clinic and community level that will deliver high volume ART safely to stable 
patients in the context of limited resources.  
The good virological and regime durability documented in this study is a motivation for the 
decentralization and mainstreaming of ART services to stable patients. This is in line with 
recommendations from the Development of Antiretroviral Therapy in Africa (DART) trail that 
shows that treatment outcomes are as good with simple clinical monitoring compared with 
clinical and laboratory monitoring. (35) 
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5 Conclusion 
Good quality data on enrolment (starters), retention in care (strugglers) and virological 
outcomes is available at TC Newman CDC and can be used to benefit patients directly and 
indirectly.Access to ART expanded rapidly at the clinic and the number of patients enrolled 
(starters) is closely related to developments and scale-up events at the clinic. 
Retention in care rate over the 6 years (63,5%-73.5%) equal those in other published 
treatment cohorts. The high ‘loss to follow-up” rate is of concern and needs further 
investigation. (strugglers)  
Good virological outcomes over time were documented for the patients in care (stayers). 
 
6 Recommendations: 
 
6.1 Data capturing and analysing 
The implementation of the electronic data register at TC Newman CDC opened opportunities 
for better data quality and the use of the electronic data register is recommended. In the face 
of the rapid increase of patient numbers, a balance between the needs for services provision 
and collection of good quality data is needed. A study looking at the impact of implementing 
the e-register on service provision and to validate data quality in the e-register is needed.  
 
6.2 Starters 
Despite progress made with the enrolment on to ART, a lot of people are still in need of 
ART. Clear enrolment targets are need and strategies enhancing the enrolment need to be 
implemented and studied. Sub-groups, like men, are more difficult to enrol and justify 
investigation.  
 
6.3 Strugglers 
It is recommended that retention in care be used as an indication of the quality of care. A 
better understanding of reasons for not returning to care at the clinic is needed and need 
further investigation. The reasons for patients dying on treatment and for early mortality need 
investigation. 
 
6.4 Stayers 
The stable patients on treatment are an ever growing group of patients and form the bulk of 
the patients visiting the clinic. It is recommended that facilities define the minimum package 
of services needed to ensure safe ART to this group of patients.   
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